Drug intelligence / Profile preview

TCG-24

Development stage: Preclinical
Modality: Small Molecules

Overview

TCG-24 (also known as TC-G 24) is a potent and selective small-molecule inhibitor of glycogen synthase kinase-3β (GSK-3β), with an IC50 of 17.1 nM. It exhibits high selectivity over related kinases such as CDK2. Chemically, it is an oxadiazole derivative that is brain-penetrant, allowing it to cross the blood-brain barrier. In rodent models, TCG-24 has been shown to increase liver glycogen reserves. It is primarily used as a research tool to investigate the role of GSK-3β in various conditions, including type 2 diabetes mellitus, Alzheimer's disease, and stroke. Currently, it is not an approved therapeutic and is distributed by multiple research chemical suppliers.

Other names: N-(3-Chloro-4-methylphenyl)-5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine

Targets

GSK3 (Glycogen synthase kinase 3 beta)

Beyond the preview

Go deeper on TCG-24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCG-24.

Explore the full profile